ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2025
Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2025-2026.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Promoting influenza vaccination among health professionals in Canada: Results of an online survey on Facebook.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- Impact of Vaccines Across the Lifespan: A New Perspective in Public Health-Conclusions of an Expert Panel-Part 2.Vaccines · 2026Review
- mRNA-based seasonal influenza vaccines: an overview of immunogenicity, efficacy, and safety.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The National Advisory Committee on Immunization (NACI) reviews the evolving evidence on influenza immunization and provides annual recommendations regarding the use of seasonal influenza vaccines. The NACI Objective: To summarize the 2025-2026 NACI seasonal influenza vaccine recommendations and to highlight new and updated information. Methods: For the development of the Results: Key updates for the 2025-2026 influenza season include: 1) removal of the preferential recommendation for quadrivalent influenza vaccines in children; 2) reiteration of the safety of concurrent administration of seasonal influenza vaccines and other vaccines, including COVID-19, based on updated evidence; 3) new evidence on the protective effects of influenza vaccination on cardiovascular events; 4) updated language for Indigenous populations; and 5) addition of individuals at higher risk of avian influenza A(H5N1) exposure as a group for whom influenza vaccination is particularly important. Conclusion: NACI recommends that seasonal influenza vaccine should be offered annually to anyone six months of age and older who does not have a contraindication to the vaccine. Influenza vaccination is particularly important for people at high risk of influenza-related complications or hospitalization, people capable of transmitting influenza to those at high risk, and others as outlined in the Statement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.